Trial Profile
A Phase I Multiple Ascending Dose (MAD) Study of RO5458640, a Humanized Monoclonal Antibody Against the TNF-like Weak Inducer of Apoptosis (TWEAK) Ligand, in Patients With Advanced Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Jun 2016
Price :
$35
*
At a glance
- Drugs RG 7212 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Roche
- 30 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 01 Nov 2012 Planned End Date changed from 1 Apr 2013 to 1 May 2013 as reported by ClinicalTrials.gov.